Becton Dickinson (BDX) Q4 FY2026 revenue $5.3 billion vs $5.16 billion est.

Becton Dickinson reported fourth-quarter fiscal 2026 revenue of $5.3 billion, up 5.4% as reported and ahead of the $5.16 billion consensus estimate, with GAAP diluted EPS of $2.52 and adjusted diluted EPS of $4.15. Full-year revenue reached $19.5 billion, up 4.9%, while GAAP and adjusted diluted EPS were $5.06 and $12.70, respectively. The company said fiscal 2026 marked the completion of its separation of the Life Sciences business and its transformation into a more focused MedTech company, and it issued guidance for fiscal 2027. Cash from continuing operations rose 30.0% to $3.6 billion and free cash flow climbed 42.5% to $2.9 billion. BD also disclosed a partnership with the U.S. government under which it intends to invest $19 billion domestically over several years, including $3 billion for manufacturing expansion, in exchange for relief from future Section 232 tariffs on covered products, subject to final scope and milestones. Investors will watch the fiscal 2027 guidance details and the tariff-relief terms as the company enters its first full year as a streamlined MedTech business.